Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 2425 of 3284 entries
View as:

A Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Aclidinium Bromide 400 μg Bid on COPD Symptoms and Sleep Quality After 3 Weeks of Treatment in Patients With Stable Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Phase: N/A Priority: Normal
NCT ID: NCT02153489 Org: User:
Start: 04/30/14 End: 06/30/15 Due: 06/30/16

Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Phase: N/A Priority: Normal
NCT ID: NCT01462929 Org: User:
Start: 11/30/11 End: 05/31/12 Due: 05/31/13

Prospective Observational Multicenter Study of Patients With AH and CKD Markers in Kazakhstan (PROGRESS-CKD)

Phase: N/A Priority: Normal
NCT ID: NCT06744335 Org: User:
Start: 01/20/25 End: 04/30/26 Due: 04/30/27

Tracking Treatment Pathways in Adult Patients With Hyperkalemia.

Phase: N/A Priority: Normal
NCT ID: NCT05408039 Org: User:
Start: 07/14/22 End: 12/19/24 Due: 12/19/25

Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI

Phase: N/A Priority: Normal
NCT ID: NCT05835778 Org: User:
Start: 06/07/23 End: 07/17/26 Due: 07/17/27

PET Study in Parkinson's Disease Patients

Phase: N/A Priority: Normal
NCT ID: NCT01527695 Org: User:
Start: 04/30/12 End: 01/31/13 Due: 01/31/14

To Assess Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Type 2 Diabetes Mellitus Patients

Phase: N/A Priority: Normal
NCT ID: NCT04445714 Org: User:
Start: 04/07/21 End: 03/14/23 Due: 03/14/24

Subjective Well Being of Schizophrenic Patients in Greece

Phase: N/A Priority: Normal
NCT ID: NCT00857064 Org: User:
Start: 03/31/09 End: 10/31/09 Due: 10/31/10

Retrospective Medical Chart Review Study to Describe the Experience of SLE Patients Treated With Anifrolumab in the Early Access Programs.

Phase: N/A Priority: Normal
NCT ID: NCT06046534 Org: User:
Start: 10/27/23 End: 06/10/24 Due: 06/10/25

Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT00855166 Org: User:
Start: 02/28/09 End: 12/31/11 Due: 12/31/12

Foxiga Korea Local Phase 4 Study

Phase: N/A Priority: Normal
NCT ID: NCT02564926 Org: User:
Start: 01/05/16 End: 01/15/18 Due: 01/15/19

Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder

Phase: N/A Priority: Normal
NCT ID: NCT00329446 Org: User:
Start: 04/30/06 End: 09/30/07 Due: 09/30/08

Depiction of Prostate Cancer Treatment Alternatives in Greece

Phase: N/A Priority: Normal
NCT ID: NCT00733213 Org: User:
Start: 01/31/08 End: 03/31/09 Due: 03/31/10

Open Label Trial to Assess Iressa in Prostate Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT00635856 Org: User:
Start: 05/31/01 End: 02/28/03 Due: 02/28/04

A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT04606771 Org: User:
Start: 09/28/20 End: 03/28/25 Due: 03/28/26

A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04588298 Org: User:
Start: 11/02/20 End: 06/19/23 Due: 06/19/24

Secondary Data Analysis of Patients at Risk for CKD to Inspect CKD Prevalence, Diagnosis Rates, Diagnostic Behaviour, Treatment Patterns and Patient Characteristics

Phase: N/A Priority: Normal
NCT ID: NCT05953701 Org: User:
Start: 07/26/23 End: 09/30/23 Due: 09/30/24

Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction

Phase: N/A Priority: Normal
NCT ID: NCT04610892 Org: User:
Start: 11/04/20 End: 11/08/23 Due: 11/08/24

Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)

Phase: N/A Priority: Normal
NCT ID: NCT01817569 Org: User:
Start: 02/13/11 End: 10/03/19 Due: 10/03/20

Study to Assess Efficacy of AZD1236 in Patients With Cystic Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT00812045 Org: User:
Start: 12/31/09 End: 08/31/10 Due: 08/31/11

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04269200 Org: User:
Start: 05/05/20 End: 04/01/27 Due: 04/01/28

Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT01202591 Org: User:
Start: 12/31/10 End: 10/31/14 Due: 10/31/15

Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis

Phase: N/A Priority: Normal
NCT ID: NCT05583227 Org: User:
Start: 11/10/22 End: 03/25/27 Due: 03/25/28

Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02228369 Org: User:
Start: 11/05/14 End: 10/28/20 Due: 10/28/21

Phase IIA Study in Patients With Schizophrenia

Phase: N/A Priority: Normal
NCT ID: NCT00686998 Org: User:
Start: 05/31/08 End: 03/31/09 Due: 03/31/10